Analyst Actions: BMO Lifts Medtronic PT to $94 vs $87, Raises 2018, 2019 Revenue Estimate 11:11 AM ET, 05/26/2017 - MT Newswires 11:11 AM EDT, 05/26/2017 (MT Newswires) -- BMO, a brokerage, said it has increased its price target and 2018 and 2019 revenue estimates for Medtronic (MDT), citing better than expected sales in its fiscal Q4 of 2017 and the company's product pipeline. The securities firm said on Friday in a note it increased the 2018 revenue forecast to $31.21 billion, reflecting 4.5% organic growth, from $31.06 billion previously, and its 2019 revenue estimate to $32.77 billion, from $32.60 billion previously. BMO also increased its price target for the stock to $94 from $87 while retaining an outperform rating. BMO left its $4.98 EPS estimate for 2018 and its $5.43 EPS estimate for 2019 unchanged. The new products driving growth include the launch of Medtronic's Resolute Onyx DES, coronary stent and a broadened portfolio for Transcatheter aortic valve replacement surgery with the larger 34mm valve, BMO said. "MDT's expanded product portfolio across Cardiac & Vascular, Minimally Invasive Therapy, Restorative Therapy, and Diabetes franchises, along with its healthy cash flow, dividend yield, and valuation, make it a compelling investment," BMO analyst JoanneÂ K.Â Wuensch said in the note.
The scenarios are quite interesting at current levels for MDT. check out awe-someSTOCKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
INO to $50 or buyout? New HIV vaccine 100% response! Love MDT long term.
Pharma stocks should do well soon as soon as next week.
Medtronic (MDT) Tops Q4 Earnings, Sales on Balanced Growth
Medtronic plc's (MDT) fourth-quarter fiscal 2017 adjusted earnings per share came in at $1.33, a couple of cents ahead of the Zacks Consensus Estimate.
MDT should buy Fitbit.
See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states: • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days • Woundcare market is over $6 Billion with high growth rate • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost • Sales could commence late 2017 • Sales and or licensing agreement/s could be very significant and fast • Company is now commercializing several other disruptive products in large markets
Hot move: short sell AXSM! Sell now, worth .02 cents.
MDT Medtronic must be very good in whatever they do. Where ever doctor's office that I go to, I see their advertisement. They must be number one in what they do. This stock is for long term investment. Short time investors please go else where.
Look like most health care and drug stocks all up in their stock prices. Must be my love in the health care and drug companies sectors.
I am so excite. My brother Joe is coming to U.S.A. today. I hope he got what he wishing for this trip.
You all know Dow index will not turn around until it tries to reach 21,000 , right?
I like the price action here. Thanks guys and gals for helping. Time to reach to new highs. This is a good company to own.
I can't complain about the price action in the last couple of days. It could be that an FDA approval for MDT's TAVR in intermediate risk patients is close, as mentioned in the article on Yahoo news about Edwards Lifesciences:
"Before investors get used to the company's recent growth spurt, it's important to realize its valve-replacement advantage over Medtronic might not last much longer. Last summer Edwards Lifesciences' Sapien 3 valves became the first to earn approval from the U.S. Food and Drug Administration for use in patients deemed at intermediate risk of not surviving the standard open-heart valve replacement surgery.
The agency's decision made the Sapien 3 the only replacement valve available for patients seen as having a 3% to 15% chance of not surviving open-heart surgery. Last month, Medtronic announced results from a successful clinical trial that will probably result in its own replacement valves entering the same space. Investors will want to keep their eyes peeled for signs the Sapien 3 valves can continue landing punches with the industry's fiercest competitor in the ring."
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
What is the expected reaction in the stock price when the divestiture of the supplies business to Cardinal is completed?
MDT should buy Fitbit.
"April 07, 2017: Citigroup names Medtronic as their new Top Pick. Citigroup also reiterates their Buy rating on the stock. Citigroup says semi-annual survey of 40 US endocrinologists has come back significantly more positive for MDT, with: (1) big share gain expectations for both the pumps and CGM segments, and (2) positive read-through for ability of 670G to drive strong overall volume growth and market expansion. Citi says it has become increasingly positive on Medtronic in the past few months and now officially makes it their top pick in the sector for the rest of 2017 (replacing BSX and ISRG)."
U have NEWS NOW.....
Nice to see a little strength on a down day. The next planned events will be the Annual Shareholders meeting, Q4 & YE results and outlook, ant he next dividend declaration.
Medtronics big three product announcements, TAVR, MICRA and the 670G are all expected to see robust demand. If the 670G improves the lives Type 1 diabetes patients then Medicare approval could follow. Were I Type 1, I would buy it and pay monthly fees. This looks good for revenue growth. The destruction of the 630G to the 670G product bridge when the 670G was approved less than 2 months after the 630G hurt Q2 revenues and knocked the stock down to the low $70's. We'll see shortly if 6 months has turned that around from a drag to a revenue boost Q4.
A dark horse catalyst is the possible sale of medical supply products. A $500 mil per year revenue number was mentioned as the base for a possible 10x revenue sale price of $5 bil. They may be able to use sale cash to buy back stock or pay down debt. The Puerto Rico tax case settlement could also be finalized -- pending lawsuits are always 50-50.
I hope today is followed by some good news.
I wonder how Boston Scientific's purchase will affect MDT.